N Acetyl Semax Amidate.

N Acetyl Semax Amidate is a research compound in the cognitive neuropeptides.

Its biological effect is described in the mechanism section.

It draws interest for cognitive neuropeptides.

F-tier evidence: human evidence is limited; most support is preclinical.

What it is

N-Acetyl-Semax-amidate is a doubly end-modified synthetic analogue of Semax, the Russian-developed heptapeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH (an ACTH(4-7) fragment extended at the C-terminus with Pro-Gly-Pro). The "N-acetyl" prefix denotes acetylation of the N-terminus and "amidate" denotes a C-terminal carboxamide; both are standard medicinal-chemistry modifications intended to blunt exopeptidase cleavage. It belongs to the melanocortin/ACTH-derived neuropeptide class and, like its parent, is marketed only as a non-pharmaceutical "research" peptide outside Russia — it is not the form studied in the published Semax clinical literature.

How it works

The mechanism attributed to this compound is inferred from the parent peptide Semax, which is devoid of the corticotropic hormonal activity of ACTH. The best-characterized action is upregulation of brain-derived neurotrophic factor (BDNF) and its TrkB receptor in the hippocampus and frontal cortex, alongside increased nerve growth factor (NGF) expression, supporting effects on neuroplasticity and neuronal survival. Semax also modulates monoaminergic (dopaminergic and serotonergic) signaling and the brain enkephalin/opioid system, and shows anti-inflammatory/immunomodulatory effects, including suppression of pro-inflammatory mediator transcripts after experimental brain ischemia. The N-terminal acetylation and C-terminal amidation are theorized to slow peptidase degradation of the very short native peptide (Semax plasma half-life is only minutes), but how these modifications alter receptor engagement, brain penetration, and the BDNF response specifically has not been characterized in peer-reviewed work.

What the evidence shows

Critically, essentially all human and animal evidence cited for this product concerns unmodified Semax, not the N-acetyl-amidate analogue, for which I found no dedicated peer-reviewed pharmacology or clinical studies — vendor claims of "improved stability/activity" for the modified form are not backed by published data. For the parent peptide, rodent studies show Semax raises BDNF/TrkB and NGF expression in hippocampus and cortex (e.g., Dolotov et al., J Neurochem 2006; Shadrina et al., Mol Biol 2011) and reduces ischemia-induced pro-inflammatory transcripts (Medvedeva et al., Mol Biol 2021). Human data come almost entirely from Russian trials of intranasal Semax in ischemic stroke (e.g., Gusev/Skvortsova-era work and Zhurnal nevrologii i psikhiatrii reports such as the 2018 efficacy analysis), where it is an approved drug; these trials predate or fall short of modern multi-center, blinded Western standards and have not been independently replicated outside Russia. The honest summary: mechanistic and preclinical plausibility is reasonable for Semax, rigorous human efficacy evidence is limited and geographically narrow, and for the acetyl-amidate variant specifically the human-vs-preclinical gap is effectively total.

Safety considerations

No formal toxicology, pharmacokinetic, or controlled safety data exist for N-Acetyl-Semax-amidate specifically; safety inferences rest entirely on unmodified intranasal Semax, which has a generally favorable tolerability record in Russian clinical use, with reported effects typically limited to mild local nasal irritation. Because the chemical modifications change the molecule, the parent peptide's safety record cannot be assumed to transfer. Long-term safety, immunogenicity, drug interactions, and effects of chronic neurotrophic-system stimulation are unstudied, and material sold as "research use only" is not manufactured to pharmaceutical quality standards, so purity and contamination are real unknowns. It is not an approved drug or supplement in the US, EU, or most jurisdictions, and is not intended for human use as sold.

Regulatory status

Unmodified Semax is a government-approved pharmaceutical in Russia (intranasal, on the Russian List of Vital and Essential Medicines) for indications such as ischemic stroke and cognitive/CNS conditions, but it is not FDA-approved and has no marketing authorization in the US or EU. N-Acetyl-Semax-amidate has no approval anywhere and is sold only as a research-use-only chemical; it is not a WADA-listed prohibited substance by name, though peptide nootropics fall in an evolving regulatory area.

1. [1]Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain — Journal of Neurochemistry, 2006, PMID 16635254
2. [2]The effect of semax and its C-end peptide PGP on the expression of neurotrophins and their receptors in the rat brain during incomplete global ischemia — Molecular Biology (Molekuliarnaia biologiia), 2011, PMID 22295573
3. [3]The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain — Molecular Biology (Molekuliarnaia biologiia), 2021, PMID 34097675
4. [4]The efficacy of semax in the treatment of patients at different stages of ischemic stroke — Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018, PMID 29798983

• Not FDA-approved; research-only.
• Human evidence is limited, largely regional.

Stack fit

Why not D: held back by human evidence, preclinical depth, safety clarity, regulatory clarity, practical relevance.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• N Acetyl Semax Amidate is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the Cognitive neuropeptides class.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The early-evidence lane
3. Why Preliminary, and not higher or lower
4. Proven lane vs speculative lane
5. What people report
6. Regulatory status
7. What changed recently